CLASSES
OF
SKIN
FIBROBLAST
METACHROMASIA
IN
CYSTIC
FIBROSIS
CORRELATED
WITH
CLINICAL
PARAMETERS
A
RETROSPECTIVE
STUDY
OF
CLINICAL
AND
RADIOLOGICAL
LUNG
SYMPTOMS
AND
INTENSITY
OF
TREATMENT
OF
98
PATIENTS
WITH
CYSTIC
FIBROSIS
WAS
CONDUCTED
THE
RESULTS
WERE
CORRELATED
TO
CLASS
OF
SKIN
FIBROBLAST
METACHROMASIA
FOURTEEN
PATIENTS
BELONGED
TO
CLASS
I
VESICULAR
METACHROMASIA
52
TO
CLASS
II
GENERALIZED
METACHROMASIA
AND
32
TO
CLASS
III
NO
METACHROMASIA
ALL
PATIENTS
ABOVE
16
YEARS
OF
AGE
SIX
PATIENTS
WERE
CLASS
II
SIMPLE
SCORING
SYSTEMS
FOR
CLINICAL
LUNG
SYMPTOMS
AND
FOR
TREATMENT
OF
LUNG
DISEASE
WERE
DEVELOPED
WHEN
COMPARED
AT
THE
SAME
AGES
CLASS
I
AND
III
PATIENTS
WERE
MORE
SEVERELY
AFFECTED
JUDGED
BY
THE
CLINICAL
LUNG
SYMPTOMS
THAN
CLASS
II
PATIENTS
AND
THEY
HAD
BEEN
MORE
INTENSIVELY
TREATED
COMPARING
CLASS
I

II
PATIENTS
METACHROMATIC
FIBROBLASTS
WITH
CLASS
III
PATIENTS
AMETACHROMATIC
FIBROBLASTS
IT
WAS
FOUND
THAT
CLASS
III
PATIENTS
WERE
MORE
SEVERELY
AFFECTED
AND
HAD
BEEN
MORE
INTENSIVELY
TREATED
THAN
CLASS
I

II
PATIENTS
AS
REGARDS
CHEST
RADIOGRAPHS
JUDGED
BY
NORMANS
SYSTEM
A
SIMILAR
PATTERN
WAS
SEEN
BUT
NO
STATISTICALLY
SIGNIFICANT
DIFFERENCES
WERE
FOUND
IN
68
PATIENTS
9
OF
CLASS
I
35
OF
CLASS
II
AND
24
OF
CLASS
III
THE
SERUM
PROTEIN
ELECTROPHORETIC
FRACTIONS
WERE
STUDIED
IT
WAS
FOUND
THAT
CLASS
III
PATIENTS
HAD
MORE
SEVERE
ALTERATIONS
THAN
CLASS
II
PATIENTS
AND
MORE
THAN
CLASS
I

II
PATIENTS
THE
PROPORTION
OF
FEMALE
PATIENTS
IN
CLASS
III
WAS
GREATER
THAN
IN
THE
OTHER
TWO
CLASSES
BUT
THIS
COULD
NOT
EXPLAIN
THE
DIFFERENCES
BECAUSE
OF
THE
SMALL
NUMBER
OF
PATIENTS
IN
CLASS
I
THE
DIFFERENCES
BETWEEN
CLASS
I
AND
CLASS
II
PATIENTS
ARE
MORE
DOUBTFUL
THAN
THE
DIFFERENCES
BETWEEN
CLASS
III
AND
CLASS
II
PATIENTS
OR
BETWEEN
CLASS
III
AND
CLASS
I

II
PATIENTS
